Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

International Prognostic Index (IPI)

The International Prognostic Index (IPI) was developed to predict the prognosis of patients with aggressive non-Hodgkin lymphoma, specifically Diffuse Large B-Cell Lymphoma (DLBCL).

Evidence-based context for fast calculator use

Purpose:
International Prognostic Index predicts overall survival in diffuse large B-cell lymphoma to guide R-CHOP chemotherapy intensity decisions.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Age > 60 years?, Ann Arbor Stage III or IV?, Serum LDH > Normal?, ECOG Performance Status ≥ 2?, More than 1 Extranodal Site?
Reference:
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
HomeInternational Prognostic Index (IPI)
Pin your most used calculators here by clicking the star in the dropdown.

International Prognostic Index (IPI)

Clinical Context & Background

The International Prognostic Index (IPI) was developed to predict the prognosis of patients with aggressive non-Hodgkin lymphoma, specifically Diffuse Large B-Cell Lymphoma (DLBCL). It is calculated based on five adverse prognostic factors.
Primary Source EvidenceThe International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
Formula Logic
Sum of risk factors (Age, Stage, LDH, PS, Extranodal).

Reference Data

Risk GroupScore5-Year Overall Survival
Low Risk0 - 173%
Low-Intermediate251%
High-Intermediate343%
High Risk4 - 526%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use International Prognostic Index (IPI) when international Prognostic Index predicts overall survival in diffuse large B-cell lymphoma to guide R-CHOP chemotherapy intensity decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age > 60 years?, Ann Arbor Stage III or IV?, Serum LDH > Normal?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should International Prognostic Index (IPI) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can International Prognostic Index (IPI) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.